nL-CHCHD-001

N/A

Report date: 2026/03/27 20:01:50
NME

Base Information

Drug NamenL-CHCHD-001
Drug Alias NamePersonalized Antisense Oligonucleotide Therapy(Mayo Clinic)nL-CHCHD-001
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesN-Lorem FoundationMayo Clinic
China Registration ClassN/A

Develop Information

Active CompaniesN-Lorem FoundationMayo Clinic
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A